RGD Reference Report - A tumor-associated splice-isoform of MAP2K7 drives dedifferentiation in MBNL1-low cancers via JNK activation. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

A tumor-associated splice-isoform of MAP2K7 drives dedifferentiation in MBNL1-low cancers via JNK activation.

Authors: Ray, Debleena  Yun, Yu Chye  Idris, Muhammad  Cheng, Shanshan  Boot, Arnoud  Iain, Tan Bee Huat  Rozen, Steven G  Tan, Patrick  Epstein, David M 
Citation: Ray D, etal., Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16391-16400. doi: 10.1073/pnas.2002499117. Epub 2020 Jun 29.
RGD ID: 155230826
Pubmed: PMID:32601196   (View Abstract at PubMed)
PMCID: PMC7368273   (View Article at PubMed Central)
DOI: DOI:10.1073/pnas.2002499117   (Journal Full-text)

Master splicing regulator MBNL1 shapes large transcriptomic changes that drive cellular differentiation during development. Here we demonstrate that MBNL1 is a suppressor of tumor dedifferentiation. We surveyed MBNL1 expression in matched tumor/normal pairs across The Cancer Genome Atlas and found that MBNL1 was down-regulated in several common cancers. Down-regulation of MBNL1 predicted poor overall survival in breast, lung, and stomach adenocarcinomas and increased relapse and distant metastasis in triple-negative breast cancer. Down-regulation of MBNL1 led to increased tumorigenic and stem/progenitor-like properties in vitro and in vivo. A discrete set of alternative splicing events (ASEs) are shared between MBNL1-low cancers and embryonic stem cells including a MAP2K7∆exon2 splice variant that leads to increased stem/progenitor-like properties via JNK activation. Accordingly, JNK inhibition is capable of reversing MAP2K7∆exon2-driven tumor dedifferentiation in MBNL1-low cancer cells. Our work elucidates an alternative-splicing mechanism that drives tumor dedifferentiation and identifies biomarkers that predict enhanced susceptibility to JNK inhibition.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
breast cancer  HEP 155230826mRNA:splice variant:exon 2: (human)RGD 
breast cancer  ISOMAP2K7 (Homo sapiens)155230826; 155230826mRNA:splice variant:exon 2: (human)RGD 
colon cancer  HEP 155230826mRNA:splice variant:exon 2: (human)RGD 
colon cancer  ISOMAP2K7 (Homo sapiens)155230826; 155230826mRNA:splice variant:exon 2: (human)RGD 
prostate cancer  HEP 155230826mRNA:splice variant:exon 2: (human)RGD 
prostate cancer  ISOMAP2K7 (Homo sapiens)155230826; 155230826mRNA:splice variant:exon 2: (human)RGD 
stomach cancer  HEP 155230826mRNA:splice variant:exon 2: (human)RGD 
stomach cancer  ISOMAP2K7 (Homo sapiens)155230826; 155230826mRNA:splice variant:exon 2: (human)RGD 
urinary bladder cancer  HEP 155230826mRNA:splice variant:exon 2: (human)RGD 
urinary bladder cancer  ISOMAP2K7 (Homo sapiens)155230826; 155230826mRNA:splice variant:exon 2: (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Map2k7  (mitogen activated protein kinase kinase 7)

Genes (Mus musculus)
Map2k7  (mitogen-activated protein kinase kinase 7)

Genes (Homo sapiens)
MAP2K7  (mitogen-activated protein kinase kinase 7)


Additional Information